CUTISS receives a new patent in the USA

(CONNECT) CUTISS AG, which specializes in skin grafts, has been granted a new patent in the USA for a core element of its automated platform for the production of human skin grafts, according to a press release. This protects a key component of the automated tissue engineering process for denovoSkin, which is currently in the late phase of clinical development for skin surgery, the company states in the press release.

To date, CUTISS has collaborated with the technology innovation center CSEM in Neuchâtel NE and innovation promoter Innosuisse in Bern on developments to automate its technology. According to the press release, this work will now be continued with Tecan, a company based in Männedorf ZH that specializes in laboratory automation. The new patent supports CUTISS' broader strategy to industrialize personalized skin tissue therapy through standardization, reproducibility and scalability.

denovoSkin, as described by CUTISS, is a personalized, bioengineered dermo-epidermal skin graft that is harvested from a small biopsy of the patient's healthy skin and expanded to produce large amounts of new skin. The aim is to significantly reduce the need to remove healthy skin, scarring and the need for subsequent surgical interventions.

CUTISS was founded in 2017 as a spin-off of the University of Zurich and is based at the Bio-Technopark Schlieren-Zurich. ce/gba